Drug intelligence / Profile preview

avisetron

Development stage: Unknown
Lead developer: Avineuro Pharmaceuticals
Modality: Small Molecules

Overview

Avisetron (AVN-211) is a highly selective small molecule antagonist of the serotonin 6 (5-HT6) receptor, developed by Avineuro Pharmaceuticals for the treatment of schizophrenia. The drug exhibits high affinity for the 5-HT6 receptor (Ki = 2.1 nM) and demonstrates significant selectivity over other therapeutic targets. In clinical studies, avisetron has shown potential in improving positive symptoms and cognitive function in patients with schizophrenia. It has progressed into Phase 2/3 clinical trials and is also being explored for its potential utility in treating Alzheimer's disease.

Other names: avisetron

Targets

HTR2B (5-Hydroxytryptamine Receptor 2B)HTR6 (5-hydroxytryptamine receptor 6)

Beyond the preview

Go deeper on avisetron.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on avisetron.

Explore the full profile